{"url_path":"/sec/adil/8-k/2026-06-11/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-11","source_url":"https://www.sec.gov/Archives/edgar/data/1513525/0001213900-26-067711-index.html","accession_number":"0001213900-26-067711","cik":"0001513525","ticker":"ADIL","issuer_name":"ADIAL PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1513525/0001213900-26-067711-index.html","primary_entity_key":"0001513525","primary_entity_name":"ADIAL PHARMACEUTICALS, INC."},"word_count":473,"has_tables":true,"body_markdown":"**Item 7.01 - Regulation FD Disclosure.**\n\n \n\nOn June 11, 2026, the Company issued a press\nrelease announcing the Merger, the Financing and related transactions and made available Azora’s investor presentation to be used\nin general corporate communications and investor communications. Copies of the press release and presentation are furnished as Exhibits\n99.1 and 99.2, respectively, to this Current Report. \n\n \n\nThe information in Item 7.01 of this Current\nReport, including the information in the press release attached as Exhibit 99.1 and the presentation attached as Exhibit 99.2 to this\nCurrent Report, is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for the purposes of Section\n18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, the information\nin Item 7.01 of this Current Report, including Exhibit 99.1 and Exhibit 99.2 to this Current Report, shall not be deemed to be incorporated\nby reference in the filings of the Company under the Securities Act.\n\n \n\n11\n\n \n\n \n\n**Forward Looking Statements**\n\n \n\nCertain statements contained in this Form 8-K\nmay constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E\nof the Securities Exchange Act of 1934, as amended. The words and phrases “designed to,” “may,” “might,”\n“can,” “will,” “to be,” “could,” “would,” “should,” “expect,”\n“intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,”\n“predict,” “project,” “potential,” “likely,” “continue,” “ongoing”\nor similar expressions, or the negative of such words, are intended to identify “forward-looking statements.” These forward-looking\nstatements include, but are not limited to, statements regarding the Company, Azora, the Financing and the Merger, including regarding\nthe timing of the Initial Closing and Milestone Closings, if any, under the Purchase Agreement and Exchange Agreements, and the expected\neffects, perceived benefits or opportunities and related timing with respect thereto; the expected grant and issuance of inducement awards\nto Mr. Davidson and other Azora employees; and expectations regarding or plans for the combined company’s pipeline, including its\nongoing clinical trials and research and development programs. The Company has based these forward-looking statements on its current\nexpectations and projections about future events. Because such statements include risks and uncertainties, actual results may differ\nmaterially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to these differences\ninclude those above in this Current Report on Form 8-K and in the Company’s other filings with the SEC. Statements made herein\nare as of the date of the filing of this Current Report on Form 8-K with the SEC and should not be relied upon as of any subsequent date.\nUnless otherwise required by applicable law, the Company does not undertake, and it specifically disclaim, any obligation to update any\nforward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement."}